Sanofi drops diabetes, CV programs to focus on growth drivers

As part of its pivot towards specialty medicines and vaccines, Sanofi (Euronext:SAN; NASDAQ:SNY) said it is cutting a dozen programs from its clinical pipeline, including two diabetes candidates and four in cardiovascular indications. The pharma announced the changes during its 4Q18 earnings presentation Thursday.

Sanofi has seen waning revenues in the franchise over the last two years. Global diabetes and CV product sales were down 7.9% at constant exchange rates to €6.1 billion ($7 billion) in 2018. The sales had fallen 9.6% the prior year...